PE20130404A1 - Compuestos heterociclicos agonistas del receptor ip - Google Patents

Compuestos heterociclicos agonistas del receptor ip

Info

Publication number
PE20130404A1
PE20130404A1 PE2013000058A PE2013000058A PE20130404A1 PE 20130404 A1 PE20130404 A1 PE 20130404A1 PE 2013000058 A PE2013000058 A PE 2013000058A PE 2013000058 A PE2013000058 A PE 2013000058A PE 20130404 A1 PE20130404 A1 PE 20130404A1
Authority
PE
Peru
Prior art keywords
alkyl
halogen
optionally substituted
heterocyclic compounds
agonistic
Prior art date
Application number
PE2013000058A
Other languages
English (en)
Inventor
Steven John Charlton
Catherine Leblanc
Stephen Carl Mckeown
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20130404A1 publication Critical patent/PE20130404A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

SE REFIERE A COMPUESTOS HETEROCICLICOS DE FORMULA (Ia) DONDE A ES N O CR', EN DONDE R' ES H O ALQUILO(C1-C8) OPCIONALMENTE SUSTITUIDO CON HALOGENO; R1 ES H, ALQUILO(C1-C8) OPCIONALMENTE SUSTITUIDO CON HALOGENO, OH, ENTRE OTROS; R2 ES H, -X-Y-, -S(O)2-W-X-Y-, ENTRE OTROS, EN DONDE W Y X SON ALQUILENO(C1-C8) OPCIONALMENTE SUSTITUIDO CON HIDROXILO, HALOGENO O ALQUILO(C1-C4); Y ES CARBOXILO, TETRAZOLILO, CARBAMOILO, ENTRE OTROS; R2a ES H; R2 Y R2a SON JUNTOS OXO; R3 Y R4 SON CADA UNO H, ALCOXILO(C1-C4), OH, CN, ENTRE OTROS; R5 ES ALQUILO(C1-C8), ALCOXILO(C1-C8), ARILO(C6-C14), ENTRE OTROS; R6 ES ARILO(C6-C14), ALQUILO(C0-C4)-HETEROARILO DE 4 A 14 MIEMBROS, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ACIDO 7-(6,7-DIFENIL-3,4-DIHIDRO-1,8-NAFTIRIDIN-1(2H)-IL)-HEPTANOICO; ACIDO 7-(2,3-DIFENIL-7,8-DIHIDRO-PIRIDO[3,2-b]PIRAZIN-5(6H)-IL)-HEPTANOICO; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON AGONISTAS DEL RECEPTOR DE PROSTACICLINA (IP) SIENDO UTILES EN EL TRATAMIENTO DE HIPERTENSION ARTERIAL PULMONAR (PAH), FIBROSIS PULMONAR
PE2013000058A 2010-07-14 2011-07-14 Compuestos heterociclicos agonistas del receptor ip PE20130404A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36413510P 2010-07-14 2010-07-14

Publications (1)

Publication Number Publication Date
PE20130404A1 true PE20130404A1 (es) 2013-04-17

Family

ID=44628483

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000058A PE20130404A1 (es) 2010-07-14 2011-07-14 Compuestos heterociclicos agonistas del receptor ip

Country Status (34)

Country Link
US (2) US8754085B2 (es)
EP (1) EP2593452B1 (es)
JP (1) JP5781159B2 (es)
KR (1) KR101491938B1 (es)
CN (1) CN103097385B (es)
AU (1) AU2011278279C1 (es)
BR (1) BR112013000946B1 (es)
CA (1) CA2804744C (es)
CL (1) CL2013000104A1 (es)
CO (1) CO6660445A2 (es)
CR (1) CR20130012A (es)
CU (1) CU24147B1 (es)
CY (1) CY1118819T1 (es)
DK (1) DK2593452T3 (es)
EA (1) EA022046B1 (es)
EC (1) ECSP13012385A (es)
ES (1) ES2622519T3 (es)
GT (1) GT201300018A (es)
HR (1) HRP20170617T1 (es)
HU (1) HUE031710T2 (es)
IL (1) IL224164A (es)
LT (1) LT2593452T (es)
MA (1) MA34373B1 (es)
MX (1) MX2013000537A (es)
MY (1) MY156795A (es)
NZ (1) NZ605528A (es)
PE (1) PE20130404A1 (es)
PL (1) PL2593452T3 (es)
PT (1) PT2593452T (es)
RS (1) RS55856B1 (es)
SG (1) SG186989A1 (es)
SI (1) SI2593452T1 (es)
UA (1) UA109786C2 (es)
WO (1) WO2012007539A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS55856B1 (sr) 2010-07-14 2017-08-31 Novartis Ag Heterociklična jedinjenja agonisti ip receptora
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
ES2561353T3 (es) 2012-01-13 2016-02-25 Novartis Ag Sales de un agonista del receptor IP
AR089698A1 (es) 2012-01-13 2014-09-10 Novartis Ag Compuestos heterociclicos antagonistas del receptor ip
US20140357641A1 (en) 2012-01-13 2014-12-04 Novartis Ag IP receptor agonist heterocyclic compounds
EP2802583A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
US9115129B2 (en) 2012-01-13 2015-08-25 Novartis Ag Substituted pyrido[2,3-B]pyrazines as IP receptor agonists
CN105189500A (zh) 2013-02-13 2015-12-23 诺华股份有限公司 Ip受体激动剂杂环化合物
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
CN106458980A (zh) 2014-04-24 2017-02-22 诺华股份有限公司 作为磷脂酰肌醇3‑激酶抑制剂的氨基吡啶衍生物
MX2016013812A (es) 2014-04-24 2017-03-09 Novartis Ag Derivados de amino-pirazina como inhibidores de fosfatidil-inositol-3-cinasa.
CN106458966B (zh) 2014-04-24 2019-05-07 诺华股份有限公司 作为磷脂酰肌醇3-激酶抑制剂的吡嗪衍生物
US9611201B2 (en) 2015-03-05 2017-04-04 Karos Pharmaceuticals, Inc. Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
MX2019000548A (es) * 2016-07-12 2019-10-30 Revolution Medicines Inc 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostericos de shp2.
EP3554507A1 (en) 2016-12-14 2019-10-23 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
TWI800498B (zh) 2016-12-21 2023-05-01 義大利商吉斯藥品公司 作為Rho-激酶抑制劑之雙環二氫嘧啶-羧醯胺衍生物
MX2019008695A (es) 2017-01-23 2019-09-11 Revolution Medicines Inc Compuestos biciclicos como inhibidores alostericos de shp2.
CA3051054A1 (en) 2017-01-23 2018-07-26 Revolution Medicines, Inc. Pyridine compounds as allosteric shp2 inhibitors
ES2866152T3 (es) 2017-01-30 2021-10-19 Chiesi Farm Spa Derivados de tirosina amida como inhibidores de la Rho-quinasa
BR112020000962A2 (pt) * 2017-07-18 2020-07-14 Nuvation Bio Inc. compostos de 1,8-naftiridinona e usos dos mesmos
EP3654978A4 (en) 2017-07-18 2021-03-31 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AS ADENOSIN ANTAGONISTS
WO2019048479A1 (en) 2017-09-07 2019-03-14 Chiesi Farmaceutici S.P.A. DERIVATIVES OF TYROSINE ANALOGS AS INHIBITORS OF RHO-KINASE
RU2020115095A (ru) 2017-10-12 2021-11-12 Революшн Медсинз, Инк. Пиридиновые, пиразиновые и триазиновые соединения в качестве аллостерических ингибиторов shp2
SG11202004090YA (en) 2017-12-15 2020-05-28 Revolution Medicines Inc Polycyclic compounds as allosteric shp2 inhibitors
WO2019121223A1 (en) 2017-12-18 2019-06-27 Chiesi Farmaceutici S.P.A. Meta tyrosine derivatives as rho-kinase inhibitors
AR113947A1 (es) 2017-12-18 2020-07-01 Chiesi Farm Spa Derivados de azaindol como inhibidores de rho-quinasa
MA51284A (fr) 2017-12-18 2021-05-26 Chiesi Farm Spa Dérivés d'oxadiazole en tant qu'inhibiteurs de kinase rho
AR114926A1 (es) 2018-06-13 2020-10-28 Chiesi Farm Spa Derivados de azaindol como inhibidores de rho-quinasa
TW202019923A (zh) 2018-07-16 2020-06-01 義大利商吉斯藥品公司 作為Ｒｈｏ－激酶抑制劑之酪胺酸醯胺衍生物
CN113613655A (zh) * 2019-01-18 2021-11-05 诺维逊生物股份有限公司 化合物及其用途
MX2021008650A (es) 2019-01-18 2021-11-03 Nuvation Bio Inc Compuestos heterociclicos como antagonistas de adenosina.
US11254670B2 (en) 2019-01-18 2022-02-22 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
MX2023005865A (es) 2020-12-15 2023-06-05 Chiesi Farm Spa Derivados de dihidrofuropiridina como inhibidores de rho-cinasa.
CN116568304A (zh) 2020-12-15 2023-08-08 奇斯药制品公司 作为rho-激酶抑制剂的二氢呋喃并吡啶衍生物
AU2021402528A1 (en) 2020-12-15 2023-07-27 Chiesi Farmaceutici S.P.A. Dihydrofuropyridine derivatives as rho- kinase inhibitors
WO2023110700A1 (en) 2021-12-13 2023-06-22 Chiesi Farmaceutici S.P.A. Dihydrofuropyridine derivatives as rho-kinase inhibitors

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1454864A (en) 1974-03-05 1976-11-03 Wyeth John & Brother Ltd Thioureas
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
AU658646B2 (en) 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
CA2090283A1 (en) 1992-02-28 1993-08-29 Nobuyuki Hamanaka Phenoxyacetic acid derivatives
US5516652A (en) 1993-10-06 1996-05-14 Merck Frosst Canada Inc. DNA encoding prostaglandin receptor IP
EP0753528A4 (en) 1994-02-10 1999-03-10 Ono Pharmaceutical Co PROTAGLANDIN I 2? RECEPTOR
WO1996035713A1 (en) 1995-05-08 1996-11-14 Pfizer, Inc. Dipeptides which promote release of growth hormone
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
TWI242011B (en) 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
US6166037A (en) 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
UA71586C2 (en) 1998-12-04 2004-12-15 Smithkline Beecham Corp A vitronectin receptor antagonist
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
RU2299206C9 (ru) 1999-05-04 2007-11-20 Шеринг Корпорейшн Производные пиперазина, фармацевтические композиции, их содержащие, и применение в качестве антагонистов ccr5
KR100439357B1 (ko) 1999-05-04 2004-07-07 쉐링 코포레이션 Ｃｃｒ５ 길항제로서 유용한 피페리딘 유도체
GB9914255D0 (en) 1999-06-18 1999-08-18 Lilly Forschung Gmbh Pharmaceutical compounds
EG24179A (en) 1999-09-07 2008-09-28 Smithkline Beecham Corp Vitronectin receptor antagonists
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
CZ2002961A3 (cs) 1999-09-17 2002-08-14 Millennium Pharmaceuticals, Inc. Benzamidy a příbuzné sloučeniny pro inhibici faktoru Xa
SK8012002A3 (en) 1999-11-08 2002-10-08 Merck & Co Inc Process for the preparation of imidazolidinone alfagammabeta3/alfagammabeta5 integrin antagonists and intermediates obtained by this method
EP1274700B1 (en) 2000-01-03 2004-11-17 Pharmacia Corporation Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders
MXPA02007688A (es) 2000-02-08 2002-12-13 Smithkline Beecham Corp Metodo y composiciones para tratar una enfermedad antiinflamatoria.
HUP0300188A3 (en) * 2000-03-16 2004-07-28 Hoffmann La Roche Carboxylic acid derivatives as ip antagonists, process for their preparation and pharmaceutical compositions containing them
US7119207B2 (en) 2000-04-10 2006-10-10 Pfizer Inc Benzoamide piperidine containing compounds and related compounds
JP4001486B2 (ja) 2000-04-10 2007-10-31 ファイザー・プロダクツ・インク ベンゾアミドピペリジン含有化合物及び関連化合物
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
TWI316055B (es) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
AR037517A1 (es) 2001-11-05 2004-11-17 Novartis Ag Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
JPWO2003068753A1 (ja) 2002-02-14 2005-06-02 小野薬品工業株式会社 Ｎ−カルバモイル窒素含有縮合環化合物およびその化合物を有効成分として含有する薬剤
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
ES2201907B1 (es) 2002-05-29 2005-06-01 Almirall Prodesfarma, S.A. Nuevos derivados de indolilpiperidina como potentes agentes antihistaminicos y antialergicos.
SE0202483D0 (sv) 2002-08-21 2002-08-21 Astrazeneca Ab Chemical compounds
JP2006096662A (ja) 2002-09-18 2006-04-13 Sumitomo Pharmaceut Co Ltd 新規６−置換ウラシル誘導体及びアレルギー性疾患の治療剤
EP1541574A4 (en) 2002-09-18 2007-06-20 Ono Pharmaceutical Co TRIAZASPIRO DERIVATIVES 5.5 | UNDECANS AND DRUGS CONTAINING THEM AS AN ACTIVE INGREDIENT
JP2004107299A (ja) 2002-09-20 2004-04-08 Japan Energy Corp 新規１−置換ウラシル誘導体及びアレルギー性疾患の治療剤
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
JP2006514964A (ja) 2003-03-12 2006-05-18 アボット・ラボラトリーズ 抗菌剤としてのナフチリジン誘導体
ES2290743T3 (es) 2003-04-30 2008-02-16 The Institutes For Pharmaceutical Discovery, Llc Heteroarilos sustituidos como inhibidores de las proteina-tirosina fosfatasas.
WO2005020926A2 (en) 2003-08-28 2005-03-10 Pharmacia Corporation Treatment or prevention of vascular disorders with cox-2 inhibitors in combination with cyclic amp-specific phosphodiesterase inhibitors
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
RU2006116421A (ru) 2003-11-25 2008-01-10 Ново Нордиск А/С (DK) Анилиды салициловой кислоты
CA2548326A1 (en) 2003-12-23 2005-07-14 Novartis Ag Bicyclic heterocyclic p-38 kinase inhibitors
GB0413960D0 (en) 2004-06-22 2004-07-28 Novartis Ag Organic compounds
AR051780A1 (es) 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
CA2608194A1 (en) 2005-05-09 2006-11-16 Hydra Biosciences, Inc. Compounds for modulating trpv3 function
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
PE20070336A1 (es) 2005-08-25 2007-04-16 Schering Corp Compuestos de indolina como agonistas de receptores adrenergicos alfa2c funcionalmente selectivos
GB0601951D0 (en) * 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US7541371B2 (en) 2006-02-20 2009-06-02 Eisai R&D Management Co., Ltd. Method for treating a motor neuron disease
US20080305169A1 (en) 2006-05-26 2008-12-11 Japan Tobacco Inc. Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds
US20080064871A1 (en) 2006-05-26 2008-03-13 Japan Tobacco Inc. Production Method of Nitrogen-Containing Fused Ring Compounds
US8163817B2 (en) 2007-05-11 2012-04-24 Canon Kabushiki Kaisha Aqueous ink, ink set, image forming method and image forming apparatus
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US20090054304A1 (en) * 2007-08-23 2009-02-26 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
EP2300425A4 (en) 2008-06-24 2012-03-21 Panmira Pharmaceuticals Llc PROSTAGLANDIN D2 RECEPTOR CYCLOALCANEÝBINDLUCK ANTAGONISTS
AU2009270984A1 (en) 2008-07-16 2010-01-21 Schering Corporation Bicyclic Heterocycle Derivatives and methods of use thereof
DE102008039082A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung
TWI368513B (en) 2009-04-30 2012-07-21 Univ Kaohsiung Medical Synthesis of pulmodil and pulmodil-1, two chlorophenylpiperazine salt derivatives, and rhokinase-dependent inhibition activity on pulmonary artery endothelium dysfunction, medial wall thickness and vascular obstruction thereof
WO2011111880A1 (ko) 2010-03-08 2011-09-15 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
RS55856B1 (sr) 2010-07-14 2017-08-31 Novartis Ag Heterociklična jedinjenja agonisti ip receptora
US20140357641A1 (en) 2012-01-13 2014-12-04 Novartis Ag IP receptor agonist heterocyclic compounds
WO2013105058A1 (en) 2012-01-13 2013-07-18 Novartis Ag 7,8- dihydropyrido [3, 4 - b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
EP2802583A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
ES2561353T3 (es) 2012-01-13 2016-02-25 Novartis Ag Sales de un agonista del receptor IP
AR089698A1 (es) 2012-01-13 2014-09-10 Novartis Ag Compuestos heterociclicos antagonistas del receptor ip
US9115129B2 (en) 2012-01-13 2015-08-25 Novartis Ag Substituted pyrido[2,3-B]pyrazines as IP receptor agonists

Also Published As

Publication number Publication date
ECSP13012385A (es) 2013-03-28
US8754085B2 (en) 2014-06-17
NZ605528A (en) 2015-02-27
UA109786C2 (xx) 2015-10-12
AU2011278279B2 (en) 2014-08-07
DK2593452T3 (en) 2017-04-24
HRP20170617T1 (hr) 2017-06-30
JP2013531025A (ja) 2013-08-01
WO2012007539A1 (en) 2012-01-19
MA34373B1 (fr) 2013-07-03
AU2011278279C1 (en) 2014-11-27
WO2012007539A9 (en) 2012-11-01
AU2011278279A1 (en) 2013-02-21
US9132127B2 (en) 2015-09-15
EA022046B1 (ru) 2015-10-30
ES2622519T3 (es) 2017-07-06
SG186989A1 (en) 2013-02-28
CO6660445A2 (es) 2013-04-30
KR20130038924A (ko) 2013-04-18
CY1118819T1 (el) 2018-01-10
EP2593452B1 (en) 2017-01-18
SI2593452T1 (sl) 2017-06-30
PL2593452T3 (pl) 2017-07-31
MY156795A (en) 2016-03-31
US20140243346A1 (en) 2014-08-28
GT201300018A (es) 2015-11-24
US20130102611A1 (en) 2013-04-25
KR101491938B1 (ko) 2015-02-10
PT2593452T (pt) 2017-04-24
CN103097385B (zh) 2016-08-03
JP5781159B2 (ja) 2015-09-16
CN103097385A (zh) 2013-05-08
LT2593452T (lt) 2017-04-10
BR112013000946A2 (pt) 2016-05-17
CL2013000104A1 (es) 2013-05-17
CA2804744C (en) 2019-05-28
MX2013000537A (es) 2013-01-29
HUE031710T2 (en) 2017-07-28
EA201300118A1 (ru) 2013-06-28
CU20130009A7 (es) 2013-04-19
EP2593452A1 (en) 2013-05-22
CR20130012A (es) 2013-02-19
CU24147B1 (es) 2016-02-29
CA2804744A1 (en) 2012-01-19
BR112013000946B1 (pt) 2020-09-08
RS55856B1 (sr) 2017-08-31
IL224164A (en) 2016-08-31

Similar Documents

Publication Publication Date Title
PE20130404A1 (es) Compuestos heterociclicos agonistas del receptor ip
PE20140234A1 (es) Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1
PE20141205A1 (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2
NZ599815A (en) N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
PE20121438A1 (es) Derivados de imidazopiridina o imidazopirimidina como inhibidores de fosfodiesterasa 10a
PE20130346A1 (es) Compuestos heterociclicos fusionados
PE20061110A1 (es) Derivados de imidazopiridina como antagonistas de la bomba de acido (apa)
PE20060299A1 (es) DIFENILIMIDAZOPIRIMIDINA E -IMIDAZOL AMINAS COMO INHIBIDORES DE ß-SECRETASA
PE20141557A1 (es) Derivado de pirazoloquinolina
PE20090049A1 (es) Derivados de piridopirimidina como moduladores de la actividad de pde 4
PE20130779A1 (es) Pirimidinas y triazinas condensadas y su uso
PE20090370A1 (es) Derivados de heterociclo fusionado como inhibidores de quinasa
PE20130651A1 (es) Derivados de imidazopiridina y su procedimiento de preparacion
PE20130576A1 (es) Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10
PE20130386A1 (es) Derivados de indolizina, su procedimiento de preparacion y su aplicacion en terapeutica
PE20071311A1 (es) Compuestos 8-azabiciclo[3.2.1]octano como antagonistas del receptor opioide mu
PE20120121A1 (es) Derivados de imidazopirazina como inhibidores de syk
PE20120629A1 (es) Compuesto triazolopiridina y su accion como inhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina
PE20121025A1 (es) Compuestos de benzoxazepina como inhibidores de la p13k
PE20130234A1 (es) Derivados de heteroaril imidazolona como inhibidores de jak
PE20090492A1 (es) Compuestos heterociclos como inhibidores de cinasa de fosfatidil-inositol-3
NZ603800A (en) Substituted 5-fluoro-1h-pyrazolopyridines and use thereof
PE20091068A1 (es) Compuestos pirrolo[3,2-d]pirimidina y su uso como inhibidores de quinasa pi3 y quinasa mtor
PE20142293A1 (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
MY176969A (en) Heterobicyclic compounds as beta-lactamase inhibitors

Legal Events

Date Code Title Description
FG Grant, registration